Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

In this study, researchers developed and tested a gel containing apocynin-loaded nanoparticles that showed promising results in treating rheumatoid arthritis in rats, suggesting potential for novel topical treatments in inflammatory conditions.

This study describes the demographic distribution of seborrheic dermatitis patients in Banda Aceh, identifying an increase in male prevalence from 2016 to 2019 and varied age group prevalence across the years.

In this case report, the authors describe a partial androgen insensitivity syndrome patient with a novel AR gene mutation, highlighting challenges in gender assignment decisions for infants with partial AIS.

In this study, researchers addressed the limitations of adenosine's practical application in treating inflammation, oxidative stress, and tissue repair due to its poor water solubility and low transdermal permeability. Results are not reported in the abstract.

This article explores the potential mechanisms by which polydeoxyribonucleotide (PDRN) could improve skin quality, slow aging, and enhance skin regeneration, but reports no new clinical findings.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This study evaluated the effects of autologous micrografts for androgenetic alopecia, reporting moderate improvements in hair loss reduction and hair density among most patients after treatment, with satisfactory results noted in patient satisfaction and treatment tolerability.

This review summarizes structural insights into androgen receptor dynamics, highlighting its flexibility in binding numerous partners, which may explain adaptive resistance mutations in cancer and loss of function in androgen insensitivity syndrome.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

This review critically evaluates the evidence for SARMs' tissue selectivity and suggests their clinical benefits over traditional androgens are not yet well-supported by robust evidence, underscoring the need for further head-to-head trials.

This study found that allergic rhinitis is linked to a higher risk of developing androgenetic alopecia, while second-generation H1-antihistamine use was associated with a reduced risk, especially in younger patients.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This review discusses the roles of androgens and androgen receptor in skin diseases like acne and hirsutism, and highlights the promise of antiandrogen drugs, reporting no new clinical findings.

This study provided the first X-ray crystal structure of the mammalian steroid hormone reductase AKR1D1 and identified a disease-related mutant, P133R, which may impact bile acid metabolism and cause clinical symptoms.

This study found that Finnish men using 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had improved disease-specific survival compared to non-users, suggesting potential benefits of the treatment.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

This report describes a case of a 19-year-old woman experiencing severe recurrent angioedema with airway issues, leading to multiple emergency visits and unsuccessful treatment with typical steroid-sparing agents.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

This study found that in men with sexual dysfunction, use of 5ARI may reduce sexual drive and spontaneous erections without worsening pre-existing erectile or ejaculatory issues.

This article discusses the crucial role of root hairs in water and nutrient uptake from soil and reports no new findings.

This study found that 5-alpha-reductase inhibitors were associated with a reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.

This case-control study from Lombardy, Italy, observed that men over 55 taking 5-alpha reductase inhibitors for benign prostatic hyperplasia were hospitalized for COVID-19 at a lower rate than age-matched controls, suggesting potential protective effects against severe disease.

This study optimized the extraction process for abomasum protein from Tianshan red deer, identifying two proteins with anti-inflammatory and anti-tumor activities, suggesting they could be beneficial in foods and nutraceuticals.

This study reports the crystallization of the human androgen receptor's ligand-binding domain with nonsteroidal ligands, which may aid in understanding the differences in binding compared to steroidal ligands.